This Integrated Healthcare Stock Rises 100% in 5 Years: Can the Demerger Push It Higher?

This integrated healthcare stock has doubled investor money over five years. A Chennai-based group that runs hospitals, a nationwide pharmacy network and a digital health app delivered a 5-year return of 100.19% as of 10 September 2026, ranking 53rd in a screen of 101 large-cap and mid-cap NSE shares.

The company is Apollo Hospitals Enterprise Ltd (NSE: APOLLOHOSP), India's largest private healthcare group by revenue. The Apollo Hospitals share price closed at approximately Rs 8,900 on 10 September 2026, up from around Rs 4,450 five years earlier, and the company is valued at approximately Rs 1,28,831 crore. Unlike many peers, this integrated healthcare stock has also kept rising over the last 12 months.

Click Here – Get Free Investment Predictions

How Much Has This Integrated Healthcare Stock Gained in 5 Years?

This integrated healthcare stock has gained approximately 100% in five years, which means Rs 1 lakh invested in September 2021 would be worth roughly Rs 2 lakh today. That works out to a compound annual return of around 14.9%.

The shorter periods are steady rather than spectacular. The 1-year return is 21.08% (rank 60) and the 3-year return is 74.58% (rank 58). Here is how this integrated healthcare stock has performed across time frames in our screen:

Period	Return (%)	Rank (out of 101)
1 Month	2.53%	61
6 Months	18.84%	66
1 Year	21.08%	60
3 Years	74.58%	58
5 Years	100.19%	53

Returns are simple price changes and are not annualised. There was no stock split or bonus issue in the five-year window, and the face value has stayed at Rs 5 per share, so the 100% figure is real price appreciation.

The 52-week range runs from around Rs 6,697 to Rs 9,050. At approximately Rs 8,900, the Apollo Hospitals share price sits within about 2% of its 52-week high and roughly 33% above its 52-week low.

Why Did This Integrated Healthcare Stock Rise 100% in 5 Years?

This integrated healthcare stock doubled because revenue grew about 72% between FY22 and FY26, profit rose about 82%, the hospital business kept lifting revenue per patient, and investors began to value the pharmacy and digital arm as a separate growth engine. The gains came in two phases, with a sharp dip in between.

1. Early Phase: Pandemic Demand and a Sharp Reset

In FY22, the company earned a net profit of about Rs 1,101 crore on revenue of approximately Rs 14,741 crore, helped by pandemic-era demand and vaccination services. This integrated healthcare stock touched fresh highs in late 2021.

That tailwind faded quickly. FY23 profit fell to around Rs 888 crore as Covid-related income disappeared and the digital platform burned cash. This integrated healthcare stock spent much of 2022 and early 2023 moving sideways, which explains why the five-year return is lower than the recent run suggests.

2. Hospitals Became More Productive

The core hospital business is the main reason this integrated healthcare stock recovered. In Q1 FY27, healthcare services revenue rose 22% to approximately Rs 3,567 crore, with a segment EBITDA margin of about 24%. Overall occupancy improved to 70% from 65% a year earlier, and average revenue per inpatient rose 8% to around Rs 1,86,630.

The group now runs approximately 9,857 census beds across 77 hospitals. Management has guided for hospital revenue growth of 18% to 20% in FY27, and established hospitals are expected to grow 13% to 14% a year over the next two years. That visibility is a key support for this integrated healthcare stock.

3. Pharmacy and Apollo 24/7 Moved Towards Profit

The pharmacy and digital arm, Apollo HealthCo, posted Q1 FY27 revenue of approximately Rs 2,977 crore, up 20%. It runs more than 7,440 offline pharmacy stores and added 151 in the quarter.

Apollo 24/7 was once the biggest worry for this integrated healthcare stock. The digital platform's losses narrowed to approximately Rs 9.7 crore in Q1 FY27 from about Rs 48.7 crore a year earlier. It has around 49 million registered users, and management expects full breakeven by Q3 FY27.

4. The HealthCo Demerger Unlocks Value

The biggest recent re-rating trigger for this integrated healthcare stock is the plan to demerge and separately list the pharmacy distribution and digital business. The tribunal approved the scheme on 5 May 2026, and listing is targeted for the January to March 2027 quarter.

Management is targeting annualised HealthCo revenue of about Rs 25,000 crore by Q4 FY27, with an exit EBITDA margin of 6.5% to 7%. Investors who believe the separate listing will reveal hidden value have supported this integrated healthcare stock through 2026.

5. Capacity Pipeline of 5,800 Beds

The company plans to add more than 5,800 beds over the next five years, taking capacity to around 14,100 beds by FY31. In Q1 FY27 it opened a 180-bed hospital in Sarjapur, Bengaluru, and added 148 beds through expansions in Indore and Guwahati. A steady pipeline gives this integrated healthcare stock visible growth for several years.

Check the Univest Screener for Live Fundamentals of High-Return Stocks

What Makes This Integrated Healthcare Stock Different?

This integrated healthcare stock is different because it earns money at almost every step of a patient's journey, not just inside a hospital. The group reports three main segments, and each has its own growth driver.

Healthcare services, which covers the hospitals, contributed about half of Q1 FY27 revenue and most of the profit. Apollo HealthCo, which covers the pharmacy stores, distribution and the Apollo 24/7 app, brought in roughly 42% of revenue. Apollo Health and Lifestyle, which runs clinics, diagnostics and day-care centres, added approximately Rs 499 crore, up 15%.

This mix gives this integrated healthcare stock more than one engine. When hospital growth slows, pharmacy volumes can keep revenue moving, and the app feeds patients into both. The trade-off is that pharmacy margins are thin, so investors in this integrated healthcare stock watch the blended margin closely.

The group has also trimmed non-core assets to focus capital. It agreed to sell its fertility and maternity business for approximately Rs 1,550 crore, freeing funds for new hospitals and the digital platform. Such moves have helped this integrated healthcare stock keep debt in check while expanding.

Integrated Healthcare Stock Financials: Profit Up 38% in Q1 FY27

The latest numbers show this integrated healthcare stock is growing profit faster than revenue. Q1 FY27 revenue grew about 21% year on year, while net profit rose around 38% to Rs 610 crore as margins widened.

Quarter	Revenue (Rs Cr)	EBITDA (Rs Cr)	Net Profit (Rs Cr)	Net Margin (%)
Jun 2025	5,882	892	441	7.41
Sep 2025	6,358	996	494	7.57
Dec 2025	6,530	1,018	516	7.98
Mar 2026	6,649	1,055	551	8.01
Jun 2026	7,092	1,141	610	8.24

Revenue figures include other income. For this integrated healthcare stock, profit has risen for four straight quarters, and net margin has improved from 7.41% to 8.24% over the last five quarters.

On a full-year basis, FY26 revenue was approximately Rs 25,420 crore, up about 16%, and net profit grew around 33% to Rs 2,003 crore. Diluted EPS climbed from Rs 62.50 in FY24 to Rs 134.94 in FY26. Operating cash flow reached approximately Rs 2,856 crore in FY26, which funded capital spending of about Rs 1,962 crore.

Valuation of This Integrated Healthcare Stock

The stock trades at a trailing PE of approximately 58.8 times, below the industry PE of around 68.5. The price-to-book ratio is about 13.5, and return on equity is approximately 20.5%. Debt to equity stood at about 0.69 at the end of FY26, and the dividend yield is a modest 0.23%. In short, this integrated healthcare stock is expensive in absolute terms but not out of line with its sector.

Who Owns This Integrated Healthcare Stock?

Foreign institutions are the largest owners of this integrated healthcare stock, holding 41.5% in June 2026. Domestic institutions have been steadily buying while foreign investors have trimmed their stake.

Quarter	Promoters (%)	FII (%)	DII (%)	Public (%)
Jun 2025	29.34	43.49	21.34	5.83
Sep 2025	28.02	44.20	21.12	6.66
Dec 2025	28.02	43.54	21.51	6.94
Mar 2026	28.02	42.62	22.76	6.60
Jun 2026	28.02	41.50	23.72	6.77

Promoter holding dipped from 29.34% to 28.02% in the September 2025 quarter and has been stable since. DII holding rose from 21.34% to 23.72% over the year, which suggests local funds have been absorbing foreign selling in this integrated healthcare stock.

Risks for This Integrated Healthcare Stock

This integrated healthcare stock carries real risks despite its strong run. Investors should weigh these before deciding on an entry point.

1. Rich Valuation

At around 59 times earnings and over 13 times book value, a lot of future growth is already priced in. Any slowdown in hospital growth or a delay in the demerger could hit this integrated healthcare stock hard.

2. Demerger Execution

The HealthCo listing depends on regulatory approvals and market conditions. If the listing is delayed beyond March 2027 or values the business below expectations, some of the recent premium in this integrated healthcare stock could fade.

3. New Hospital Drag and Rising Debt

New hospitals usually lose money in their first two to three years. With more than 5,800 beds in the pipeline and capital spending near Rs 2,000 crore a year, borrowings may rise and early losses could weigh on margins.

4. Pricing Regulation and Competition

Government moves to cap procedure or drug prices, or changes to insurance rates, could squeeze margins. Competition from other large chains and online pharmacies adds further pressure on this integrated healthcare stock. The pharmacy arm in particular faces aggressive discounting from quick-commerce and e-pharmacy players.

Download the Univest iOS App or Univest Android App to track the Apollo Hospitals share price live

Apollo Hospitals Share: Analyst View

Analysts remain broadly positive on the Apollo Hospitals share after the Q1 FY27 results. They highlight margin expansion, falling digital losses and the demerger as the three main drivers for this integrated healthcare stock.

Apollo Hospitals Share Price Target

After the Q1 FY27 results in August 2026, a domestic brokerage set an Apollo Hospitals share price target of Rs 10,446 with a buy rating, implying about 17% upside from around Rs 8,900. In May 2026, two other domestic brokerages set targets of Rs 9,660 and Rs 9,350.

The highest Apollo Hospitals share price target mentioned above sits well above the 52-week high of Rs 9,050. A decisive move past that level would put the Apollo Hospitals share price in new territory, while the 52-week low near Rs 6,697 marks the main support. Any Apollo Hospitals share price target is an estimate and not a promise of returns.

Conclusion

This integrated healthcare stock has doubled in five years on the back of more productive hospitals, a larger pharmacy network and a digital arm that is nearing breakeven. The 21% gain over the last year shows that momentum has held up better than at many peers.

The Apollo Hospitals share price now reflects high expectations, with a PE near 59 and the HealthCo listing still ahead. For long-term investors, this integrated healthcare stock offers a diversified healthcare story, but position sizing and patience matter at current valuations.

Frequently Asked Questions

Which integrated healthcare stock rose 100% in 5 years?

Ans. Apollo Hospitals Enterprise Ltd (NSE: APOLLOHOSP) delivered a 5-year return of approximately 100.19% as of 10 September 2026. The share rose from around Rs 4,450 to approximately Rs 8,900 over that period.

What is the Apollo Hospitals share price today?

Ans. The Apollo Hospitals share price closed at approximately Rs 8,900 on 10 September 2026. Its 52-week range is around Rs 6,697 to Rs 9,050.

Why did the Apollo Hospitals share rise over 5 years?

Ans. The rise came from strong growth in the hospital business, a larger pharmacy network, narrowing losses at Apollo 24/7 and the planned demerger of Apollo HealthCo. Net profit grew from about Rs 1,101 crore in FY22 to Rs 2,003 crore in FY26.

What is the Apollo Hospitals share price target?

Ans. After the Q1 FY27 results, a domestic brokerage set a target of Rs 10,446 with a buy rating. Other domestic brokerages set targets of Rs 9,660 and Rs 9,350 in May 2026.

How did Apollo Hospitals perform in Q1 FY27?

Ans. Revenue grew about 21% year on year to over Rs 7,000 crore, and net profit rose around 38% to Rs 610 crore. Hospital occupancy improved to 70% from 65%.

When will Apollo HealthCo be listed?

Ans. The company has targeted the listing of the demerged pharmacy and digital business in the January to March 2027 quarter. The tribunal approved the scheme on 5 May 2026.

Is Apollo Hospitals share overvalued?

Ans. The stock trades at a PE of around 58.8 times, which is below the industry PE of about 68.5 but high in absolute terms. Investors should consider growth visibility and demerger timing before deciding.

Did Apollo Hospitals issue a bonus or split shares in the last 5 years?

Ans. No. There was no stock split or bonus issue in the five-year window, and the face value remains Rs 5 per share. The 100% return reflects genuine price appreciation.